Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
1999 1
2000 3
2001 1
2005 2
2006 3
2007 4
2008 1
2009 1
2010 2
2011 1
2012 3
2013 6
2014 5
2015 5
2016 10
2017 6
2018 8
2019 11
2020 18
2021 13
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34802047

95 results

Results by year

Filters applied: . Clear all
Page 1
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. Tan CR, et al. Bone Marrow Transplant. 2022 Feb;57(2):295-298. doi: 10.1038/s41409-021-01527-z. Epub 2021 Nov 20. Bone Marrow Transplant. 2022. PMID: 34802047 Free PMC article. No abstract available.
Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
Rassy E, Danu A, Ibrahim T, Lazarovici J, Ghez D, Michot JM, Arfi-Rouche J, Rossignol J, Vergé V, Dartigues P, Ribrag V. Rassy E, et al. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e373-e380. doi: 10.1016/j.clml.2020.11.008. Epub 2020 Nov 13. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33277224
Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Roussel M, Rannigan L, Gibbs SDj, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD. Venner CP, et al. Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5. Haematologica. 2014. PMID: 25193959 Free PMC article. No abstract available.
Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis.
Muchtar E, Dispenzieri A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Leung N, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Fonder A, Hobbs M, Go RS, Rajkumar SV, Kyle RA, Hogan WJ, Gertz MA. Muchtar E, et al. Transplant Cell Ther. 2021 Jul;27(7):589.e1-589.e6. doi: 10.1016/j.jtct.2021.03.031. Epub 2021 Apr 8. Transplant Cell Ther. 2021. PMID: 33839316 Free article.
Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T 3rd, Damon L, Andreadis CB. Kambhampati S, et al. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):246-256.e2. doi: 10.1016/j.clml.2020.11.005. Epub 2020 Nov 11. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33288485
95 results